[英文調查報告書] 抗真菌劑：全球

Abstract

INTRODUCTION

Fungi are highly resistant microbiological agents. In other words, they are resistant to compounds designed to eradicate them through the various antifungal mechanisms of action such as disrupting reproductive capabilities, destroying cell walls, or modifying fungal DNA and cell functioning. Fungal infections and infestations in humans, animals, plants, and the environment are also on the rise, with many having lethal consequences. As such, BCC was particularly interested in examining the antifungal market growth for current products, market shift for those products that are now relegated to OTC status previously having only been provided by prescription, and to identify new antifungal research, development, new drug applications, and novel approaches to the market.

SCOPE OF STUDY

This report contains:

An examination of the major markets for antifungal applications in human healthcare, veterinary healthcare, agriculture and the environment/buildings
Analysis of each market segment on the global level, with current market status, and forecasts for growth over the next five years to 2012
Highlights and reviews of FDA restrictions, government legislation, as well as discussions on fungal resistance and changes in consumer preferences, such as a greater demand for OTC medications and/or natural and alternative remedies
Presentation of new drug and patent applications, new methods of drug administration, drug discovery and development, and various clinical trials and applications
Profiles for important companies

INFORMATION SOURCES

Of the companies and agencies surveyed, the majority were pharmaceutical or compound manufacturers. Additional information was supplied by known industry/trade sources.

ANALYST CREDENTIALS

Danielle West is a doctor of naturopathy who has worked extensively consulting with individuals previously diagnosed with fungal infections. In addition to her naturopathic consulting practice, Dr. West is a known speaker and guest lecturer, and has authored numerous articles and several books on healthcare. She has an extensive background ghostwriting peer reviewed journal articles for the medical profession.

INTRODUCTION
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THIS STUDY
- CONTRIBUTIONS TO THE STUDY AND FOR WHOM
- SCOPE AND FORMAT
- METHODOLOGY
- INFORMATION SOURCES
- ANALYST CREDENTIALS
- RELATED BCC REPORTS
- DISCLAIMER
SUMMARY
- Summary Table:
- GLOBAL MARKET FORECAST FOR ANTIFUNGAL AGENTS, THROUGH 2012 ($ MILLIONS)
- Summary Figure:
- GLOBAL ANTIFUNGAL AGENT SALES BY MARKET SEGMENT, 2005 AND 2012 (%)
OVERVIEW
- HISTORY AND CURRENT STATE OF ANTIMICROBIALS
- Table 1 DEATHS ATTRIBUTABLE TO MICROBIOLOGIC PATHOGENS IN HISTORY
  - TYPES OF ANTIMICROBIALS
    - BACTERIA
    - VIRUSES
    - PROTOZOA
    - FUNGI
  - DEFINITION OF THE INDUSTRY
  - CONCEPTS IN THE INDUSTRY
  - IMPORTANCE OF THE INDUSTRY
  - PRODUCT LIFE CYCLES
- Table 2 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG
  - DEVELOPMENT OF ANTIFUNGALS
  - FUTURE DEVELOPMENTS
    - 2006 NEW DRUG ACTIVITY
    - 2005 NEW DRUG ACTIVITY
  - WITH AN EYE TOWARD THE FUTURE
TYPE OF APPLICATIONS: HUMAN HEALTHCARE, VETERINARY, AGRICULTURE, AND ENVIRONMENTAL
- TYPE OF APPLICATIONS: HUMAN HEALTHCARE
- HUMAN FUNGAL INFECTIONS
  - RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS
- Table 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
  - CANDIDIASIS
    - Cutaneous Candidiasis
    - Chronic Mucocutaneous Candidiasis
    - GI Tract Candidiasis
    - Respiratory Tract Candidiasis
    - Genitourinary Tract Candidiasis
    - Hepatosplenic Candidiasis
    - Systemic Candidiasis
      - Candidemia
      - Disseminated Candidiasis
  - ASPERGILLOSIS
  - BLASTOMYCOSIS
  - COCCIDIOIDOMYCOSIS
  - CRYPTOCOCCOSIS
  - DERMATOPHYTOSIS
  - HISTOPLASMOSIS
  - ONYCHOMYCOSIS
  - PARACOCCIDIOIDOMYCOSIS
  - PSEUDALLESCHERIASIS
  - SPOROTRICHOSIS
  - ZYGOMYCOSIS
- Table 4 INCIDENCE OF COMMON FUNGAL DISEASES
  - HUMAN ANTIFUNGAL AGENTS
- Table 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2012 ($ MILLIONS)
  - ECHINOCANDINS
  - ANTIMETABOLITES
  - AZOLES
  - POLYENES
  - OTHER
- Table 6 ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES VS. OTHERS THROUGH 2009 ($ MILLIONS)
- Table 7 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
- Figure 1 PERCENTAGE ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
- Table 8 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE
- Table 9 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY
- Table 10 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT
  - SIDE EFFECTS
- Table 11 LIFE THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS
  - OVER THE COUNTER ANTIFUNGAL PREPARATIONS
- Table 12 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION
  - NATURAL ANTIFUNGAL COMPLEXES
    - Herbal Antifungal Agents
- Table 13 COMMON HERBAL ANTIFUNGALS
  - Enzyme-Based Antifungal Agents
- Table 14 COMMON ENZYMES USED IN NATURAL ANTIFUNGAL PRODUCTS
  - Homeopathic Antifungal Agents
- LABORATORY TESTING AND HISTOPATHOLOGY FOR FUNGAL INFECTIONS IN HUMANS
  - SPECIMEN EXAMINATION
  - CULTURES
  - BLOOD SEROLOGY
- ALTERNATIVE HEALTHCARE APPROACHES TO TESTING AND DIAGNOSIS OF FUNGAL INFECTIONS
  - CAM TESTING AND SPECIALIZED LABORATORIES
  - QUESTIONNAIRE FOR SYMPTOMS
    - FUNGAL RESISTANCE
- Table 15 COMMON REASONS FOR FUNGAL RESISTANCE
  - STRATEGIES TO IMPROVE RESPONSE AND DECREASE MORTALITY
VETERINARY ANTIFUNGAL SEGMENT
- THE INDUSTRY
- VETERINARY FUNGAL INFECTIONS
  - ASPERGILLOSIS
  - CANDIDIASIS
  - COCCIDIOIDOMYCOSIS
  - CRYPTOCOCCOCOSIS
  - EPIZOOTIC LYMPHANGITIS UNIQUE TO HORSES
  - GEOTRICHOSIS
  - HISTOPLASMOSIS
  - HYALOHYPHOMYCOSIS
  - MYCETOMAS
  - NORTH AMERICAN BLASTOMYCOSIS
  - OOMYCOSIS
  - PAECILOMYCOSIS
  - PENNICILLIOSIS
  - PHAEOHYPHOMYCOSIS
  - RHINOSPORIDIOSIS
  - SPOROTRICHOSIS
  - ZYGOMYCOSIS
- VETERINARY ANTIFUNGAL AGENTS
  - POLYENES
  - AZOLES
  - ANTIMETABOLITES
  - OTHER
    - Griseofulvin
    - Lufenuron
- Table 16 VETERINARY FUNGAL INFECTIONS AND PHARMACEUTICAL OPTIONS
- Table 16 (CONTINUED)
- Table 17 COMMON SIDE EFFECTS FROM VETERINARY ANTIFUNGALS
  - VETERINARY BASED LABORATORY TESTS AND HISTOLOGY
AGRICULTURAL ANTIFUNGAL SEGMENT
- THE INDUSTRY
- GOVERNMENT REGULATIONS
  - AGRICULTURE ANTIFUNGALS: MECHANISMS OF ACTION
  - AGRICULTURAL PRODUCTS AND APPLICATIONS
- Table 18 AGRICULTURAL ANTIFUNGAL ACTIVE INGREDIENTS WITH =100,000 LBS APPLIED, 2002
- Table 18 (CONTINUED)
- Table 19 ANTIFUNGAL USE BY REGION OF THE UNITED STATES, 2002
- Table 20 ANTIFUNGAL USE BY CROP TYPE, 2002
  - AGRICULTURAL SIDE EFFECTS
- Table 21 SIDE EFFECTS FROM COMMON AGRICULTURAL ANTIFUNGAL AGENTS
- Table 21 (CONTINUED)
  - AGRICULTURAL FUNGAL RESISTANCE
  - STRATEGIES TO PREVENT FUNGAL RESISTANCE IN AGRICULTURAL FUNGI
ENVIRONMENTAL ANTIFUNGAL SEGMENT
- THE INDUSTRY
- WHY ENVIRONMENTAL MOULD IS A UNIQUE PROBLEM
- COMMON ENVIRONMENTAL MOULDS
  - ALTERNARIA
  - ASPERGILLUS
  - CLADOSPORIUM
  - PENICILLIUM
    - HEALTH RISKS DUE TO ENVIRONMENTAL FUNGI AND MOULD
- Table 22 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOULDS
- Table 23 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOULD REACTIONS
- Table 24 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOULDS
GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS
- GOVERNMENT REGULATIONS
  - FOOD AND DRUG ADMINISTRATION
- Table 25 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA 1997-2006
- Table 25 (CONTINUED)
  - ENVIRONMENTAL PROTECTION AGENCY (EPA)
  - UNITED STATED DEPARTMENT OF AGRICULTURE (USDA)
  - FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS
- PROFESSIONAL ASSOCIATIONS
  - MEDICAL AND VETERINARY ASSOCIATIONS
  - AGRICULTURAL ASSOCIATIONS
  - OTHER ENVIRONMENTAL ASSOCIATIONS
MAJOR ANTIFUNGAL MANUFACTURERS
- HUMAN HEALTHCARE
  - PHARMACEUTICAL MANUFACTURERS
- Table 26 MAJOR ANTIFUNGAL HUMAN PHARMACEUTICAL MANUFACTURERS
- Table 26 (CONTINUED)
- Figure 2 PERCENTAGE OF ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY
- Table 27 MAJOR PHARMACEUTICAL ANTIFUNGAL MANUFACTURERS, 2006 ($ MILLION)
  - MAJOR PHARMACEUTICAL MANUFACTURER PROFILES
    - Astellas
    - Barrier Therapeutics
    - Enzon Pharmaceuticals
    - Gilead Sciences, Inc.
    - Medicis
    - Teva Pharmaceutical USA
    - Novartis
    - Pfizer, Inc.
    - Schering-Plough Corp.
    - SciClone Pharmaceuticals, Inc.
    - Taro Pharmaceutical Industries, Ltd.
    - York Pharma
  - MAJOR OTC ANTIFUNGAL MANUFACTURERS
    - PHARMACEUTICAL OTC MARKET
- Table 28 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS
  - PHARMACEUTICAL-BASED OTC MANUFACTURER PROFILES
    - Alva-Amco Pharmacal
    - Blaine Labs
    - Dartmouth Pharmaceuticals
    - Del Laboratories
    - Dermik
    - Ganeden Biotech
    - McNeil Consumer and Specialty Pharmaceuticals
    - Kramer Laboratories
    - Novartis
    - Pedinol Pharmacal
    - Pfizer
    - Schering-Plough
    - Stiefel Laboratories
    - Tarmac Products
  - ALTERNATIVE OTC MARKET
- Table 29 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS
  - ProSymbiotics
  - Nature' s Plus
  - Aqua Flora
  - NOW Foods
  - Rainbow Light
  - Enzymedica
  - Pure Essence Laboratories
  - Michael' s Naturopathic Programs
  - Renew Life
  - Garden of Life
  - Nutrition Now
  - Solaray
  - Vitanica
  - Forest Herbs Research
  - Crystal Star Herbal Nutrition
- VETERINARY MARKET
- Table 30 MAJOR VETERINARY ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS AND PRODUCTS
- Table 30 (CONTINUED)
- Figure 3 PERCENTAGE OF MANUFACTURERS OF VETERINARY ANTIFUNGALS BY COUNTRY (%)
  - MAJOR VETERINARY ANTIFUNGAL MANUFACTURER PROFILES
    - Argent
    - Bioniche Life Science
    - Butler Animal Health
    - Durvet Animal Health Products
    - Med-Pharmex
    - Virbac
    - Schering-Plough Animal Health
    - Stiefel
    - Vetoquinol
    - Vedco
    - Wyeth Animal Health
  - AGRICULTURAL ANTIFUNGAL MANUFACTURERS
- Table 31 MAJOR AGRICULTURAL ANTIFUNGAL MANUFACTURERS
- Figure 4 PERCENT AGRICULTURAL ANTIFUNGAL MANUFACTURERS BY COUNTRY (%)
  - MAJOR AGRICULTURAL MANUFACTURER PROFILES
    - AgriChem
    - AgraQuest
    - Albaugh, Inc.
    - American Vanguard
    - Arysta Life Sciences
    - BASF
    - Bayer CropScience
    - Makhteshim Agan of North America, Inc.
    - Cerexagri
    - Chemtura
    - Dow AgroSciences
    - DuPont Crop Protection
    - Gowan
    - JH Biotech
    - Helena Chemical Company
    - Nordox AS
    - Nufarm
    - Syngenta
    - Valent
ANTIFUNGAL INDUSTRY
- ANTIFUNGAL MARKET TRENDS: HUMAN HEALTHCARE
  - ACCELERATING ANTIFUNGAL DRUG DEVELOPMENT
- Table 32 PHARMACEUTICAL ANTIFUNGAL PRODUCTS IN THE PIPELINE, 2006
- Table 33 NEW PRESCRIPTION ANTIFUNGALS, 2005-2006
  - INCREASED TYPES OF TESTING
    - Need to Increase Use and Acceptance of Newer Drugs
    - Trends in Class Used and Administration Method
- Table 34 PHARMACEUTICAL ANTIFUNGALS BY ADMINISTRATION TYPE (%)
- Figure 5 PERCENTAGE OF PHARMACEUTICAL ANTIFUNGAL PRODUCTS BY ADMINISTRATION TYPE (%)
- Table 35 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ADMINISTRATION, THROUGH 2012 ($ MILLIONS)
  - UTILIZATION OF OTC AND NATURAL/ALTERNATIVE ANTIFUNGAL AGENTS
    - Shifting Market from Prescription to OTC
- Table 36 COMPANIES WITH PRODUCTS SHIFTING FROM PRESCRIPTION ANTIFUNGALS TO OTC STATUS
- Table 37 SALES SHIFT FROM PHARMACEUTICAL TO OTC, 2005 ($ MILLIONS)
  - Market Demand for OTC Products
- ANTIFUNGAL MARKET TRENDS: VETERINARY HEALTH
- ANTIFUNGAL MARKET TRENDS-AGRICULTURAL
  - DECREASE IN NUMBER OF MANUFACTURERS
  - DECREASE IN PRICE PER POUND OF SYNTHETIC AGENTS
  - INCREASED PRODUCTION AND DISTRIBUTION OF GENERICS
  - INCREASE IN FUNGAL RESISTANCE IN PHYTOMYCOTIC ORGANISMS
PATENT ANALYSIS
- PURPOSE OF A PATENT ANALYSIS
- DUE CARE IN REVIEWING THE PATENT ANALYSIS
  - NEW ANTIFUNGAL PATENTS ISSUED
- Table 38 ANTIFUNGAL PATENT TRENDS, 1990-2006
- Table 38 (CONTINUED)
- Figure 6 ANTIFUNGAL PATENT TRENDS, 1990-2006
- Table 39 PATENT BY ANTIFUNGAL MARKET SEGMENT, 1990-2006
- Table 40 NEW ANTIFUNGAL PATENTS ISSUED, 2005-2006
- Table 40 (CONTINUED)
- Table 40 (CONTINUED)
- Table 40 (CONTINUED)
- Table 41 ASSIGNEES OF THREE OR MORE PATENTS FOR ANTIFUNGAL PRODUCTS, 2005-2006
- Table 42 PATENT TRENDS BY COUNTRY, 2005-2006
- Figure 7 NEW ANTIFUNGAL PATENT APPROVALS BY COUNTRY, 2005-2006 (%)
  - TRENDS IN PATENT APPLICATIONS
- Table 43 PATENT APPLICATION TRENDS, 2001-2006
- Figure 8 ANTIFUNGAL PATENT APPLICATIONS BY YEAR, 2001-2006 (%)
- Table 44 PATENT APPLICATIONS BY ANTIFUNGAL SEGMENT, 2001-2006
- Figure 9 PERCENTAGE OF PATENT APPLICATIONS BY ANTIFUNGAL MARKET SEGMENT, 2001-2006 (%)
- Table 45 NEW PATENT APPLICATIONS, 2005-2006
- Table 45 (CONTINUED)
- Table 45 (CONTINUED)
- Table 46 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MARKET SEGMENT, 2005-2006
- Table 47 PATENT APPLICATION TRENDS BY COUNTRY, 2005-2006
- Figure 10 ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY, 2005-2006 (%)
  - PATENT EXPIRATIONS
- Table 48 PATENT EXPIRATIONS, 2006-2011
APPENDIX
- Table 49 PHARMACEUTICAL COMPANIES
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
- Table 49 (CONTINUED)
LIST OF TABLES
- Summary Table:
- GLOBAL MARKET FORECAST FOR ANTIFUNGAL AGENTS, THROUGH 2012 ($ MILLIONS)
- Table 1 DEATHS ATTRIBUTABLE TO MICROBIOLOGIC PATHOGENS IN HISTORY
- Table 2 DRUG DEVELOPMENT LIFECYCLE FOLLOWING DISCOVERY OF NEW DRUG
- Table 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
- Table 4 INCIDENCE OF COMMON FUNGAL DISEASES
- Table 5 GLOBAL MARKET FORECAST FOR HUMAN ANTIFUNGAL CONSUMPTION BY PRODUCT TYPE, THROUGH 2012 ($ MILLIONS)
- Table 6 ANTIFUNGAL PHARMACEUTICAL SALES: TRIAZOLES VS. OTHERS THROUGH 2009 ($ MILLIONS)
- Table 7 PHARMACEUTICAL ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
- Table 8 MAJOR ANTIFUNGAL AGENTS BY CLASS AND AVERAGE SALES PRICE PER DOSAGE
- Table 9 FUNGAL INFECTION AND TRADITIONAL PHARMACEUTICAL REMEDY
- Table 10 TYPE OF CANDIDAL INFECTION AND PHARMACEUTICAL TREATMENT
- Table 11 LIFE THREATENING SIDE EFFECTS FROM ANTIFUNGAL PHARMACEUTICALS
- Table 12 COMMON FUNGAL INFECTIONS AND OTC ROUTES OF ADMINISTRATION
- Table 13 COMMON HERBAL ANTIFUNGALS
- Table 14 COMMON ENZYMES USED IN NATURAL ANTIFUNGAL PRODUCTS
- Table 15 COMMON REASONS FOR FUNGAL RESISTANCE
- Table 16 VETERINARY FUNGAL INFECTIONS AND PHARMACEUTICAL OPTIONS
- Table 17 COMMON SIDE EFFECTS FROM VETERINARY ANTIFUNGALS
- Table 18 AGRICULTURAL ANTIFUNGAL ACTIVE INGREDIENTS WITH =100,000 LBS APPLIED, 2002
- Table 19 ANTIFUNGAL USE BY REGION OF THE UNITED STATES, 2002
- Table 20 ANTIFUNGAL USE BY CROP TYPE, 2002
- Table 21 SIDE EFFECTS FROM COMMON AGRICULTURAL ANTIFUNGAL AGENTS
- Table 22 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOULDS
- Table 23 RISK FACTORS ASSOCIATION WITH ENVIRONMENTAL MOULD REACTIONS
- Table 24 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOULDS
- Table 25 ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA 1997-2006
- Table 26 MAJOR ANTIFUNGAL HUMAN PHARMACEUTICAL MANUFACTURERS
- Table 27 MAJOR PHARMACEUTICAL ANTIFUNGAL MANUFACTURERS, 2006($ MILLION)
- Table 28 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS
- Table 29 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGALS
- Table 30 MAJOR VETERINARY ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS AND PRODUCTS
- Table 31 MAJOR AGRICULTURAL ANTIFUNGAL MANUFACTURERS
- Table 32 PHARMACEUTICAL ANTIFUNGAL PRODUCTS IN THE PIPELINE, 2006
- Table 33 NEW PRESCRIPTION ANTIFUNGALS2005-2006
- Table 34 PHARMACEUTICAL ANTIFUNGALS BY ADMINISTRATION TYPE (%)
- Table 35 GLOBAL MARKET FORECAST FOR ANTIFUNGAL PHARMACEUTICAL PRODUCTS BY ADMINISTRATION, THROUGH 2012 ($ MILLIONS)
- Table 36 COMPANIES WITH PRODUCTS SHIFTING FROM PRESCRIPTION ANTIFUNGALS TO OTC STATUS
- Table 37 SALES SHIFT FROM PHARMACEUTICAL TO OTC, 2005 ($ MILLIONS)
- Table 38 ANTIFUNGAL PATENT TRENDS, 1990-2006
- Table 39 PATENT BY ANTIFUNGAL MARKET SEGMENT1990-2006
- Table 40 NEW ANTIFUNGAL PATENTS ISSUED, 2005-2006
- Table 41 ASSIGNEES OF THREE OR MORE PATENTS FOR ANTIFUNGAL PRODUCTS, 2005-2006
- Table 42 PATENT TRENDS BY COUNTRY, 2005-2006
- Table 43 PATENT APPLICATION TRENDS, 2001-2006
- Table 44 PATENT APPLICATIONS BY ANTIFUNGAL SEGMENT, 2001-2006
- Table 45 NEW PATENT APPLICATIONS, 2005-2006
- Table 46 RECENT TRENDS IN PATENT APPLICATIONS FOR ANTIFUNGALS BY MARKET SEGMENT, 2005-2006
- Table 47 PATENT APPLICATION TRENDS BY COUNTRY, 2005-2006
- Table 48 PATENT EXPIRATIONS, 2006-2011
- Table 49 PHARMACEUTICAL COMPANIES
LIST OF FIGURES
- Summary Figure:
- GLOBAL ANTIFUNGAL AGENT SALES BY MARKET SEGMENT, 2005 AND 2012 (%)
- Figure 1 PERCENTAGE ANTIFUNGALS BY CLASS/MECHANISM OF ACTION (%)
- Figure 2 PERCENTAGE OF ANTIFUNGAL PHARMACEUTICAL MANUFACTURERS BY COUNTRY
- Figure 3 PERCENTAGE OF MANUFACTURERS OF VETERINARY ANTIFUNGALS BY COUNTRY (%)
- Figure 4 PERCENT AGRICULTURAL ANTIFUNGAL MANUFACTURERS BY COUNTRY (%)
- Figure 5 PERCENTAGE OF PHARMACEUTICAL ANTIFUNGAL PRODUCTS BY ADMINISTRATION TYPE (%)
- Figure 6 ANTIFUNGAL PATENT TRENDS, 1990-2006
- Figure 7 NEW ANTIFUNGAL PATENT APPROVALS BY COUNTRY, 2005-2006 (%)
- Figure 8 ANTIFUNGAL PATENT APPLICATIONS BY YEAR, 2001-2006 (%)
- Figure 9 PERCENTAGE OF PATENT APPLICATIONS BY ANTIFUNGAL MARKET SEGMENT, 2001-2006 (%)
- Figure 10 ANTIFUNGAL PATENT APPLICATIONS BY COUNTRY, 2005-2006 (%)

全球抗真菌劑市場

Global Markets for Antifungal Agents

Abstract

INTRODUCTION

SCOPE OF STUDY

INFORMATION SOURCES

ANALYST CREDENTIALS

Table of Contents